Knight Therapeutics Valuation
| GUD Stock | CAD 5.27 0.02 0.38% |
At this time, the firm appears to be fairly valued. Knight Therapeutics secures a last-minute Real Value of C$5.46 per share. The latest price of the firm is C$5.27. Our model forecasts the value of Knight Therapeutics from analyzing the firm fundamentals such as EBITDA of 56.82 M, price to earning of 133.90 X, and Cash And Equivalents of 302 K as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Knight Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Knight Therapeutics is based on 3 months time horizon. Increasing Knight Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Knight Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Knight Stock. However, Knight Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.27 | Real 5.46 | Hype 5.27 |
The intrinsic value of Knight Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Knight Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Knight Therapeutics helps investors to forecast how Knight stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Knight Therapeutics more accurately as focusing exclusively on Knight Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Knight Therapeutics' intrinsic value based on its ongoing forecasts of Knight Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Knight Therapeutics' closest peers.
Knight Therapeutics Cash |
|
Knight Valuation Trend
Knowing Knight Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Knight Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Knight Therapeutics Total Value Analysis
Knight Therapeutics is currently forecasted to have takeover price of 0 with market capitalization of 576.83 M, debt of 69.09 M, and cash on hands of 302 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Knight Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 576.83 M | 69.09 M | 302 K |
Knight Therapeutics Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Knight suggests not a very effective usage of assets in November.Knight Therapeutics Profitability Analysis
The company reported the revenue of 328.2 M. Net Loss for the year was (16.84 M) with profit before overhead, payroll, taxes, and interest of 0.About Knight Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Knight Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Knight Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Knight Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Knight Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Knight Therapeutics. We calculate exposure to Knight Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Knight Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 107.6 M | 54.2 M | |
| Pretax Profit Margin | (0.07) | (0.06) | |
| Operating Profit Margin | (0.01) | (0.01) | |
| Net Loss | (0.05) | (0.05) | |
| Gross Profit Margin | 0.47 | 0.65 |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.